A large-scale, collaborative, systems biology approach is needed to expedite the discovery of treatments for dry age-related macular degeneration, according to a report by a working group of scientists appointed by the National Advisory Eye Council (NAEC) that includes Joan. W. Miller, MD, Chair of Harvard Ophthalmology.
Saghar Bagheri, MD, Clinical Research Fellow at Mass. Eye and Ear under the mentorship of Dr. Demetrios Vavvas, has been invited to participate in the Members-in-Training Outstanding Poster Award Competition at the ARVO Annual Meeting. She received one of the top five scored abstracts in the Retina section for her work entitled, "Anti-VEGF non-responders are often short-term responders." The competition will take place on Tuesday, April 30, 4:15-5:45 p.m., in the Exhibit Hall. Award recipients will be recognized at the Thursday Keynote Session. ... Read more about Saghar Bagheri to Participate in ARVO Members-in-Training Outstanding Poster Award Competition
Attendance for the 3rd Biennial International Symposium on Ocular Regeneration and the 5th Biennial International Symposium on AMD continues to climb each year, reflecting the high caliber of these meetings and the value they bring to their respective fields. Both events sparked great discussions and drew rave reviews from attendees, participants, and sponsors alike.... Read more about Symposia Facilitate Dialogue on Innovative Research
Findings may lead to earlier diagnoses and better prognostic information for patients — and, potentially, new pharmaceutical targets for AMD treatment.
Boston, Mass. — Patients with any stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be found through special laboratory tests, according to a new study led by AMD researchers based at Massachusetts Eye and Ear. The study, ...
At the fourth Biennial International Symposium on AMD, held October 21-22, 2016 in Boston, more than 200 clinicians, researchers, trainees, and industry representatives discussed current AMD topics and the challenges that lay ahead. One of the central themes of this year’s symposium was the need for a more precise stratification of the disease.
A phase I/II clinical trial at Massachusetts Eye and Ear found that some patients taking high doses of atorvastatin (cholesterol-lowering medication) had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD). AMD is the leading cause of blindness in the developed world, and though effective treatments are available for the wet AMD, they are currently lacking for the more-prevalent dry form.